CD19 and acute lymphoblastic leukemia: In our previous study analyzing 254 B-ALL patients, compared to the TP53 wild-type group, patients with TP53 mutations had lower CR rates, resulting in significantly poorer OS and LFS, despite receiving CD19 CAR-T cell therapy [37].